Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus DEMEROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus DEMEROL.
BELBUCA vs DEMEROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Category C
Category C
Opioid Analgesic
Opioid Analgesic